SGRY insider sells shares; proposed 3,145-share sale on NASDAQ
Rhea-AI Filing Summary
Surgery Partners, Inc. (SGRY) submitted a Form 144 notifying a proposed sale of 3,145 common shares through UBS Financial Services with an approximate market value of 65,269.9, and an approximate sale date of 10/09/2025 on NASDAQ. The securities were acquired on 10/09/2025 via equity compensation and paid by equity option exercise.
The filing also lists multiple prior open-market sales by the named person, Wayne DeVeydt, across dates from 08/21/2025 to 10/08/2025, including several large single-day blocks (up to 150,000 shares). The notice includes the required attestation that the seller is not aware of undisclosed material adverse information.
Positive
- Full regulatory disclosure of the proposed sale via Form 144, including acquisition method (equity option exercise)
- Broker identified for the sale: UBS Financial Services, providing execution transparency
Negative
- Multiple insider sales reported from 08/21/2025 to 10/08/2025, including a block of 150,000 shares, which represent material insider liquidity over a short period
- Proposed sale scheduled for 10/09/2025 could add incremental selling supply on NASDAQ
Insights
TL;DR: Multiple recent insider sales and a proposed sale from exercised equity make insider liquidity visible to investors.
The filing shows a proposed sale of 3,145 common shares arising from an equity option exercise and executed via UBS Financial Services on 10/09/2025. The seller also conducted numerous open-market sales between 08/21/2025 and 10/08/2025, including single transactions as large as 150,000 shares.
These items increase publicly visible insider liquidity and help investors track potential supply pressure on the stock; monitor short-term trading volumes and price action around the listed sale dates over the next few trading sessions for any immediate market impact.
FAQ
What does the Form 144 filed for Surgery Partners (SGRY) disclose?
Which broker will execute the proposed sale?